文献速递胸部肿瘤

WJTOG3405最终总生存结果:吉非替尼对比顺铂联合多西他赛一线治疗EGFR突变阳性NSCLC

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer.
PubMed 文献 · Ann Oncol · 2019-01-01

WJTOG3405 III期随机试验最终OS分析纳入172例EGFR突变阳性IIIB/IV期或术后复发NSCLC患者,吉非替尼组与顺铂联合多西他赛组中位OS分别为34.9个月和37.3个月,HR 1.252(95%CI 0.883-1.775,P=0.2070),吉非替尼未显示OS优势。术后复发与IIIB/IV期疾病为独立预后因素,HR 0.459(95%CI 0.312-0.673,P<0.001)。

要点

  • 吉非替尼一线治疗EGFR突变阳性NSCLC未较顺铂联合多西他赛改善OS。
  • 中位随访59.1个月,吉非替尼组与化疗组中位OS分别为34.9和37.3个月。
  • 术后复发患者OS优于IIIB/IV期疾病,为独立预后因素。

核心结论

  • 吉非替尼作为一线治疗未较顺铂联合多西他赛显示总生存获益。
  • 术后复发患者的总生存优于IIIB/IV期疾病患者,即使两者均为转移性疾病。

研究设计与样本

  • III期随机试验WJTOG3405,比较吉非替尼与顺铂联合多西他赛一线治疗EGFR突变阳性IIIB/IV期或术后复发NSCLC。
  • 排除5例后,改良意向治疗人群共172例(每组86例)纳入生存分析。
  • 吉非替尼250 mg/日口服;顺铂80 mg/m2联合多西他赛60 mg/m2静脉给药,每21天一次,共3至6周期。
  • 数据截止2013年9月30日,中位随访时间59.1个月;采用Kaplan-Meier法和log-rank检验,Cox比例风险模型计算死亡HR。

主要发现

  • 吉非替尼组OS事件68/86(79.1%),顺铂联合多西他赛组59/86(68.6%)。
  • 吉非替尼组与顺铂联合多西他赛组中位生存时间分别为34.9个月和37.3个月,HR 1.252(95%CI 0.883-1.775,P=0.2070)。
  • 多因素分析显示术后复发和IIIB/IV期疾病为独立预后因素,HR 0.459(95%CI 0.312-0.673,P<0.001)。
  • 吉非替尼组术后复发与IIIB/IV期疾病中位生存时间分别为44.5个月和27.5个月;顺铂联合多西他赛组分别为45.5个月和32.8个月。

临床怎么用

  • 对于EGFR突变阳性晚期NSCLC一线治疗,吉非替尼虽改善PFS但未转化为OS获益,临床决策需综合考量。
  • 术后复发患者预后优于初诊IIIB/IV期患者,预后分层可参考疾病状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary analysis of the phase III study WJTOG 3405 demonstrated superiority of progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) gefitinib compared with cisplatin plus docetaxel (CD) as the first-line treatment of stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. This report presents final overall survival (OS) data. PATIENTS AND METHODS: Patients were randomized between G (250 mg/day orally) and cisplatin (80 mg/m2 intravenously) plus docetaxel (60 mg/m2 i.v.), administered every 21 days for three to six cycles. After the exclusion of 5 patients, 172 patients (86 in each group, modified intention-to-treat population) were included in the survival analysis. OS was re-evaluated using updated data (data cutoff, 30 September 2013; median follow-up time 59.1 months). The Kaplan-Meier method and the log-rank test were used for analysis, and hazard ratios (HRs) for death were calculated using the Cox proportional hazards model. RESULTS: OS events in the G group and CD group were 68 (79.1%) out of 86 and 59 (68.6%) out of 86, respectively. Median survival time for G and CD were 34.9 and 37.3 months, respectively, with an HR of 1.252 [95% confidence interval (CI): 0.883-1.775, P = 0.2070]. Multivariate analysis identified postoperative recurrence and stage IIIB/IV disease as independent prognostic factors, with an HR of 0.459 (95% CI: 0.312-0.673, P < 0.001). Median survival time (postoperative recurrence versus stage IIIB/IV disease) were 44.5 and 27.5 months in the G group and 45.5 and 32.8 months in the CD group, respectively. CONCLUSION: G did not show OS benefits over CD as the first-line treatment. OS of patients with postoperative recurrence was better than that of stage IIIB/IV disease, even though both groups had metastatic disease.This study was registered with UMIN (University Hospital Medical Information Network in Japan), number 000000539.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Yoshioka H, Shimokawa M, Seto T, et al. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Ann Oncol. 2019. PMID: 31553438. doi:10.1093/annonc/mdz399

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。